Salivary Amylase‐Responsive Buccal Tablets Wipe Out Chemotherapy‐Rooted Refractory Oral Mucositis
Open Access
- 16 January 2024
- journal article
- research article
- Published by Wiley in Advanced Science
- Vol. 11 (11) , e2308439
Abstract
Oral mucositis (OM) is the most common and refractory complication of cancer chemotherapy and radiotherapy, severely affecting patients’ life quality, lowering treatment tolerance, and discouraging patient compliance. Current OM delivery systems mostly affect the comfort of patient use and lead to poor compliance and unsatisfactory effects. Herein, salivary amylases (SAs)‐responsive buccal tablets consisting of porous manganese‐substituted Prussian blue (PMPB) nanocubes (NCs), anti‐inflammatory apremilast (Apr) and starch controller have been engineered. PMPB NCs with large surface area can serve as carriers to load Apr, and their multienzyme‐mimicking activity enables them to scavenge reactive oxygen species (ROS), which thus synergize with Apr to mitigate inflammation. More significantly, the starch controller can respond to abundant SAs in the oral cavity and realize the cascade, continuous, and complete drug release after enzymatic decomposition, which not only aids with high tissue affinity to prolong the resistance time but also improves the comfort of use. The preclinical study reveals that contributed by the above actions, such buccal tablets mitigate inflammation, promote endothelium proliferation and migration, and accelerate wound healing for repressing chemotherapy‐originated intractable OM with positive oral microenvironment and shorter recovery time, thus holding high potentials in clinical translation.Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (22120210561)
This publication has 49 references indexed in Scilit:
- Development of endogenous enzyme-responsive nanomaterials for theranosticsChemical Society Reviews, 2018
- Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosisCancer Medicine, 2017
- Prussian Blue Nanoparticles as Multienzyme Mimetics and Reactive Oxygen Species ScavengersJournal of the American Chemical Society, 2016
- Genipin-crosslinked catechol-chitosan mucoadhesive hydrogels for buccal drug deliveryBiomaterials, 2015
- Enzyme-responsive nanomaterials for controlled drug deliveryNanoscale, 2014
- Modeling the oral cavity: In vitro and in vivo evaluations of buccal drug delivery systemsJournal of Controlled Release, 2012
- The defence architecture of the superficial cells of the oral mucosaMedical Hypotheses, 2012
- Advances in oral transmucosal drug deliveryJournal of Controlled Release, 2011
- Management of Oral Mucositis in Patients Who Have CancerDental Clinics of North America, 2008
- Oral mucositis, dysfunction, and distress in patients undergoing cancer therapyJournal of Clinical Nursing, 2007